Literature DB >> 27566797

Checkpoint immunotherapy: good for cancer therapy, bad for rheumatic diseases.

Leonard Calabrese1, Vamsidhar Velcheti2.   

Abstract

Entities:  

Keywords:  Autoimmune Diseases; DMARDs (biologic); Inflammation

Mesh：

Substances：

Year:  2016        PMID： 27566797     DOI： 10.1136/annrheumdis-2016-209782

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN： 0003-4967            Impact factor:   19.103


× No keyword cloud information.
  13 in total

1.  Nivolumab-Induced Recurrence of Rheumatoid Arthritis in a Patient with Metastatic Gastric Adenocarcinoma.

Authors:  Masataka Nishikawa; Atsushi Goshima; Hajime Owaki; Takeshi Fuji
Journal:  Clin Drug Investig       Date:  2019-12       Impact factor: 2.859

Review 2.  Immunometabolism: A new target for improving cancer immunotherapy.

Authors:  Chunqing Guo; Shixian Chen; Wenjie Liu; Yibao Ma; Juan Li; Paul B Fisher; Xianjun Fang; Xiang-Yang Wang
Journal:  Adv Cancer Res       Date:  2019-04-17       Impact factor: 6.242

3.  Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline.

Authors:  Julie R Brahmer; Christina Lacchetti; Bryan J Schneider; Michael B Atkins; Kelly J Brassil; Jeffrey M Caterino; Ian Chau; Marc S Ernstoff; Jennifer M Gardner; Pamela Ginex; Sigrun Hallmeyer; Jennifer Holter Chakrabarty; Natasha B Leighl; Jennifer S Mammen; David F McDermott; Aung Naing; Loretta J Nastoupil; Tanyanika Phillips; Laura D Porter; Igor Puzanov; Cristina A Reichner; Bianca D Santomasso; Carole Seigel; Alexander Spira; Maria E Suarez-Almazor; Yinghong Wang; Jeffrey S Weber; Jedd D Wolchok; John A Thompson
Journal:  J Clin Oncol       Date:  2018-02-14       Impact factor: 44.544

4.  Immune-related adverse events and immune checkpoint inhibitor tolerance on rechallenge in patients with irAEs: a single-center experience.

Authors:  Vineel Bhatlapenumarthi; Anannya Patwari; Antoine J Harb
Journal:  J Cancer Res Clin Oncol       Date:  2021-03-28       Impact factor: 4.553

5.  Inflammatory tenosynovitis and enthesitis induced by immune checkpoint inhibitor treatment.

Authors:  Jun Inamo; Yuko Kaneko; Tsutomu Takeuchi
Journal:  Clin Rheumatol       Date:  2018-02-17       Impact factor: 2.980

6.  Immunotherapy for Metastatic Melanoma with Right Atrial Involvement in a Patient with Rheumatoid Arthritis.

Authors:  Zachary Benson; Sarah Gordon; Patricia Nicolato; Andrew Poklepovic
Journal:  Case Rep Oncol Med       Date:  2017-12-28

7.  Detect it so you can treat it: A case series and proposed checklist to detect neurotoxicity in checkpoint therapy.

Authors:  Saskia Bolz; Thivyah Ramakrishnan; Michael Fleischer; Elisabeth Livingstone; Benjamin Stolte; Andreas Thimm; Kathrin Kizina; Selma Ugurel; Christoph Kleinschnitz; Martin Glas; Lisa Zimmer; Tim Hagenacker
Journal:  eNeurologicalSci       Date:  2021-02-01

8.  Association of blood biomarkers and autoimmunity with immune related adverse events in patients with cancer treated with immune checkpoint inhibitors.

Authors:  Despina Michailidou; Ali Raza Khaki; Maria Pia Morelli; Leonidas Diamantopoulos; Namrata Singh; Petros Grivas
Journal:  Sci Rep       Date:  2021-04-27       Impact factor: 4.379

Review 9.  Apoptotic and Nonapoptotic Activities of Pterostilbene against Cancer.

Authors:  Rong-Jane Chen; Hsiao-Che Kuo; Li-Hsin Cheng; Yu-Hsuan Lee; Wen-Tsan Chang; Bour-Jr Wang; Ying-Jan Wang; Hung-Chi Cheng
Journal:  Int J Mol Sci       Date:  2018-01-18       Impact factor: 5.923

Review 10.  The Potential Regulatory Roles of Circular RNAs in Tumor Immunology and Immunotherapy.

Authors:  Zhixiao Fang; Chunjie Jiang; Shengli Li
Journal:  Front Immunol       Date:  2021-02-03       Impact factor: 7.561
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.